Microsomal antiestrogen-binding site (AEBS)

The microsomal antiestrogen-binding site (AEBS) refers to a protein complex residing in the microsomal fraction of cells, distinct from classical nuclear estrogen receptors. AEBS binds certain non-steroidal antiestrogens—particularly tamoxifen and PBPE—and mediates anti-proliferative and differentiating effects in cancer cells. Molecularly, AEBS is a hetero-oligomeric complex comprising the enzymes 3β-hydroxysterol-Δ^8^-Δ^7^-isomerase (D8D7I) and 3β-hydroxysterol-Δ^7^-reductase (DHCR7), and it carries the enzymatic activity of cholesterol-5,6-epoxide hydrolase (ChEH). Binding of AEBS ligands inhibits ChEH, causing the cellular accumulation of sterol intermediates, which modulates cell proliferation, cell death (apoptosis), and differentiation, especially in breast cancer and multiple myeloma models. The AEBS represents an alternative drug target from classical estrogen receptors, with non-genomic signaling properties. Despite its therapeutic potential, the AEBS is not a single, well-characterized molecule but an incompletely defined complex, and the scientific community considers its nomenclature and molecular identity ambiguous and outdated.

Other names

Antiestrogen-binding siteAEBSCholesterol-5,6-epoxide hydrolase (ChEH)Non-nuclear antiestrogen binding site

Inhibition of cholesterol-5,6-epoxide hydrolase activity (ChEH), leading to the accumulation of cholesterol intermediates such as zymostenol and desmosterol. Induction of apoptosis and cell differentiation through sterol accumulation. Alteration of cellular proliferation via non-estrogen-receptor pathways. Stimulating autophagy.